A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains

被引:14
作者
Hosseini, Seyed Younes
Sabahi, Farzaneh [1 ]
Amini-Bavil-Olyaee, Samad
Alavian, Seyed-Moayed
Merat, Shahin
机构
[1] Tarbiat Modares Univ, Fac Med Sci, Dept Virol, Tehran, Iran
[2] Pasteur Inst Iran, Dept Biotechnol, Tehran, Iran
[3] Baqiyatallah Univ Med Sci, Tehran Hepatitis Ctr, Tehran, Iran
[4] Univ Tehran Med Sci, Digest Dis Res Ctr, Tehran, Iran
关键词
hepatitis B virus; drug-resistance; YMDD motif; ACRS-PCR; Iranian patients;
D O I
10.1016/j.jviromet.2006.07.008
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
As a consequence of the point mutation in the YMDD motif of the hepatitis B virus (HBV) polymerase gene, lamivudine-resistant mutants have been reported in chronic hepatitis B patients who underwent lamivudine therapy. The objective of the study was to develop a novel accurate artificially created restriction site (ACRS) method with a digestion internal control for identification of YMDD, YIDD and YVDD HBV strains. Three conserved, specific and diagnostic primers introducing Ndel, SspI and AleI cleavage sites were designed in order to identify YMDD, YIDD and YVDD strains, respectively; while, their reverse primers also modified with the above recognition sites in order to enzyme correctness monitoring and false outcome avoiding. Thirty-two chronic hepatitis B patients who had taken lamivudine for 1-3 years and checked by the Inno-LiPA HBV DR kit, were evaluated by the ACRS method and then compared to sequencing data. The results of the ACRS method revealed the YMDD mutant strain in 20 patients, YMDD plus YIDD pattern in I patient, YMDD plus YVDD in 4 patients, the YIDD in 4 patients and mixed infection with each three strains in I patient. The sequencing and Inno-LiPA results were in agreement with the ACRS results. The novel ACRS method is a reliable, rapid and a cost-effective technique for determination of HBV strains with the wild type and YMDD mutant patterns. (c) 2006 Published by Elsevier B.V.
引用
收藏
页码:298 / 303
页数:6
相关论文
共 34 条
[1]   Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B [J].
Ahmed, SNS ;
Tavan, D ;
Pichoud, C ;
Berby, F ;
Stuyver, L ;
Johnson, M ;
Merle, P ;
Abidi, H ;
Trépo, C ;
Zoulim, F .
HEPATOLOGY, 2000, 32 (05) :1078-1088
[2]   Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis - an open-cohort study [J].
Akuta, N ;
Tsubota, A ;
Suzuki, F ;
Suzuki, Y ;
Hosaka, T ;
Someya, T ;
Kobayashi, M ;
Saitoh, S ;
Arase, Y ;
Ikeda, K ;
Kumada, H .
JOURNAL OF HEPATOLOGY, 2003, 38 (01) :91-97
[3]   Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine [J].
Allen, MI ;
Gauthier, J ;
DesLauriers, M ;
Bourne, EJ ;
Carrick, KM ;
Baldanti, F ;
Ross, LL ;
Lutz, MW ;
Condreay, LD .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (10) :3338-3347
[4]   Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].
Allen, MI ;
Deslauriers, M ;
Andrews, CW ;
Tipples, GA ;
Walters, KA ;
Tyrrell, DLJ ;
Brown, N ;
Condreay, LD .
HEPATOLOGY, 1998, 27 (06) :1670-1677
[5]   A novel accurate amplification created restriction site method for determination of the wild type and the precore mutant hepatitis B virus variants [J].
Amini-Bavil-Olyaee, S ;
Sarrami-Forooshani, R ;
Adeli, A ;
Mahboudi, F ;
Sabahi, F ;
Nafisi, H ;
Zali, MR ;
Azizi, M .
JOURNAL OF VIROLOGICAL METHODS, 2005, 127 (01) :19-23
[6]  
BENHAMOU Y, 2001, LANCET INFECT DIS, V358, P713
[7]   Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy [J].
Chayama, K ;
Suzuki, Y ;
Kobayashi, M ;
Kobayashi, M ;
Tsubota, A ;
Hashimoto, M ;
Miyano, Y ;
Koike, H ;
Kobayashi, M ;
Koida, I ;
Arase, Y ;
Saitoh, S ;
Murashima, N ;
Ikeda, K ;
Kumada, H .
HEPATOLOGY, 1998, 27 (06) :1711-1716
[8]   Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus [J].
Delaney, WE ;
Edwards, R ;
Colledge, D ;
Shaw, T ;
Torresi, J ;
Miller, TG ;
Isom, HC ;
Bock, CT ;
Manns, MP ;
Trautwein, C ;
Locarnini, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1705-1713
[9]   Lamivudine as initial treatment for chronic hepatitis B in the United States [J].
Dienstag, JL ;
Schiff, ER ;
Wright, TL ;
Perrillo, RP ;
Hann, HWL ;
Goodman, Z ;
Crowther, L ;
Condreay, LD ;
Woessner, M ;
Rubin, M ;
Brown, NA .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) :1256-1263
[10]   Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy [J].
Dienstag, JL ;
Schiff, ER ;
Mitchell, M ;
Casey, DE ;
Gitlin, N ;
Lissoos, T ;
Gelb, LD ;
Condreay, L ;
Crowther, L ;
Rubin, M ;
Brown, N .
HEPATOLOGY, 1999, 30 (04) :1082-1087